Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

Journal of Immunology

Volumn 173, Issue 2, 2004, Pages 1444-1453

  Viguier, Manuelle ^a,b   Lemaître, Fabrice ^a   Verola, Olivier ^c   Cho, Min Sun ^a   Gorochov, Guy ^c   Dubertret, Louis ^b   Bachelez, Hervé ^b   Kourilsky, Philippe ^a   Ferradini, Laurent ^a  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR V BETA CHAIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL CONTACT; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPH NODE METASTASIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION;

EID: 3142737258     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.2.1444     Document Type: Article

References (65)

1. Nathanson, L. 1976. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl. Cancer Inst. Monogr. 44:67.
2. Boon, T., P. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T cells. Immunol. Today 18:267.
3. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.
4. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
5. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
6. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99:16168.
7. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
8. + progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451.
9. Coulie, P. G., and P. van der Bruggen. 2003. T-cell responses of vaccinated cancer patients. Curr. Opin. Immunol. 15:131.
10. Pardoll, D. M. 1998. Cancer vaccines. Nat. Med. 4:525.
11. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.
12. Asano, M., M. Toda, N. Sakaguchi, and S. Sakaguchi. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184:387.
13. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455.
14. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389.
15. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823.
16. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211.
17. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59:3128.
18. + T regulatory cells. Nat. Immunol. 4:337.
19. + regulatory T cells. Nat. Immunol. 4:330.
20. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057.
21. Ramsdell, F. 2003. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19:165.
22. Weiner, H. L. 2001. Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells. Immunol. Rev. 182:207.
23. Roncarolo, M. G., R. Bacchetta, C. Bordignon, S. Narula, and M. K. Levings. 2001. Type 1 T regulatory cells. Immunol. Rev. 182:68.
24. + thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur. J. Immunol. 31:1247.
25. + T cells: a highly differentiated and apoptosis-prone population. Eur. J. Immunol. 31:1122.
26. + regulatory thymocytes. Blood 102:4107.
27. high regulatory cells in human peripheral blood. J. Immunol. 167:1245.
28. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193:1295.
29. - T cells. J. Clin. Invest. 112:1437.
30. + T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193:1285.
31. + T cells with regulatory properties from human blood. J. Exp. Med. 193:1303.
32. + cells: a naturally occurring population of regulatory T cells. Blood 98:2736.
33. + human thymocytes. J. Exp. Med. 196:379.
34. + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother. 26:85.
35. + regulatory T-cell levels in patients with melanoma. Clin. Cancer Res. 9:2551.
36. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 62:5267.
37. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:4766.
38. Woo, E. Y., H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll, J. L. Riley, L. R. Kaiser, and C. H. June. 2002. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168:4272.
39. Marshall, N. A., L. E. Christie, L. R. Munro, D. J. Culligan, P. W. Johnston, R. N. Barker, and M. A. Vickers. 2004. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103:1755.
40. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169:2756.
41. Balch, C. M., A. C. Buzaid, S. J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton, Jr., J. M. Kirkwood, et al. 2001. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19:3635.
42. Pannetier C., J. P. Levraud, A. Lim, J. Even, and P. Kourilsky. 1997. The Immunoscope approach for the analysis of T cell repertoires. In The Antigen T Cell Receptor: Selected Protocols and Applications. J. R. Oksenberg, ed. R. G. Landes Company, Austin, p. 287.
43. + T cell immune responses. J. Immunol. Methods 261:177.
44. Campbell, J. J., K. E. Murphy, E. J. Kunkel, C. E. Brightling, D. Soler, Z. Shen, J. Boisvert, H. B. Greenberg, M. A. Vierra, S. B. Goodman, et al. 2001. CCR7 expression and memory T cell diversity in humans. J. Immunol. 166:877.
45. Croft, M. 2003. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 14:265.
46. + regulatory T cells in the steady state. J. Exp. Med. 198:737.
47. Casanova, J. L., and J. L. Maryanski. 1993. Antigen-selected T-cell receptor diversity and self-nonself homology. Immunol. Today 14:391.
48. Mukherji, B., S. A. Wilhelm, A. Guha, and M. T. Ergin. 1986. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J. Immunol. 136:1888.
49. Mukherji, B., A. Guha, N. G. Chakraborty, M. Sivanandham, A. L. Nashed, J. R. Sporn, and M. T. Ergin. 1989. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J. Exp. Med. 169:1961.
50. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20:107.
51. Steinman, R. M., S. Turley, I. Mellman, and K. Inaba. 2000. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191:411.
52. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194:629.
53. Qin, S., S. P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, and H. Waldmann. 1993. "Infectious" transplantation tolerance. Science 259:974.
54. Modigliani, Y., A. Bandeira, and A. Coutinho. 1996. A model for developmentally acquired thymus-dependent tolerance to central and peripheral antigens. Immunol. Rev. 149:155.
55. + regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J. Exp. Med. 196:247.
56. + T helper cells. J. Exp. Med. 196:255.
57. Cobbold, S., and H. Waldmann. 1998. Infectious tolerance. Curr. Opin. Immunol. 10:518.
58. + T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195:603.
59. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192:1213.
60. Sato, T., P. McCue, K. Masuoka, S. Salwen, E. C. Lattime, M. J. Mastrangelo, and D. Berd. 1996. Interleukin 10 production by human melanoma. Clin. Cancer Res. 2:1383.
61. Van Belle, P., U. Rodeck, I. Nuamah, A. C. Halpern, and D. E. Elder. 1996. Melanoma-associated expression of transforming growth factor-β isoforms. Am. J. Pathol. 148:1887.
62. + regulatory T cells from human peripheral blood. J. Immunol. 166:7282.
63. Gorelik, L., and R. A. Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7:1118.
64. + regulatory T cells control Leishmania major persistence and immunity. Nature 420:502.
65. Gorelik, E. 1983. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv. Cancer Res. 39:71.